Picture of Embecta logo

EMBC — Embecta News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousSmall CapContrarian

Embecta Corp expected to post earnings of 40 cents a share - Earnings Preview

* Embecta Corp  EMBC.OQ   EMBC.O  is expected to show a fall
in
quarterly revenue when it reports  results on May 9 for the
period ending March 31 2024
    * The Parsippany New Jersey-based  company is expected to
report a
4.5% decrease in revenue to $264.697 million from $277.1 million
a year ago, according to the mean estimate from 3 analysts,
based on LSEG data.
    * ​LSEG's mean analyst estimate for Embecta Corp is for
earnings
of 40 cents per share. 
    * The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is no "strong buy" or "buy," 2
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Embecta
Corp is
$16.50​, above​ its last closing price of $10.39. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  LSEG IBES  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  ESTIMATE             MET,    SE %
               E®                               MISSED  
 Dec. 31 2023  0.45        0.46       0.61      Beat    34.1
 Sep. 30 2023  0.42        0.40       0.59      Beat    48.4
 Jun. 30 2023  0.46        0.46       0.26      Missed  -43.5​
 Mar. 31 2023  0.49        0.49       0.24      Missed  -50.7
 ​​Dec.        0.51        0.52       0.96      Beat    86.4
 31 2022                                                
 Sep. 30 2022  0.72        0.67       1.18      Beat    77.4​
 Jun. 30 2022  0.87        0.87       1.30      Beat    49.4
 This summary was machine generated May 7 at 17:57 GMT.  All
figures in US dollars unless otherwise stated. (For questions
concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com)

Recent news on Embecta

See all news